Free Trial

Aadi Bioscience Q3 2023 Earnings Report

Aadi Bioscience logo
$1.91 +0.01 (+0.53%)
As of 03/28/2025

Aadi Bioscience EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.73
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Aadi Bioscience Revenue Results

Actual Revenue
$5.96 million
Expected Revenue
$6.68 million
Beat/Miss
Missed by -$720.00 thousand
YoY Revenue Growth
N/A

Aadi Bioscience Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

Aadi Bioscience Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Q4 2024 Aadi Bioscience Inc Earnings Call
Six new option listings and four option delistings on March 19th
See More Aadi Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aadi Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aadi Bioscience and other key companies, straight to your email.

About Aadi Bioscience

Aadi Bioscience (NASDAQ:AADI), a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

View Aadi Bioscience Profile

More Earnings Resources from MarketBeat